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Background: Tolvaptan is the only vasopressin V2 receptor antagonist licensed by the European Medicines Agency
for the treatment of hyponatraemia (HN) secondary to the syndrome of inappropriate antidiuretic hormone secretion
(SIADH). We have investigated the cost-effectiveness of tolvaptan versus no active treatment (NAT) in adult patients
within the licensed indication who have either failed to respond to fluid restriction or for whom the use of fluid
restriction is not suitable, from the societal perspective in Sweden.
Methods: A cost-utility analysis, considering a ‘general SIADH’ population and two subpopulations of patients
(small-cell lung cancer [SCLC] and pneumonia) to broadly represent the complex clinical pathway of SIADH, was
performed. A discrete event simulation was developed to model the progression of individuals through inpatient
admissions over a 30-day time horizon (180 days for the SCLC cohort). Clinical data were derived from tolvaptan
trials and observational data sources. All costs are given in Swedish kronor (SEK).
Results: In the ‘general SIADH’ population, tolvaptan was associated with reduced costs (SEK 5,779 per patient
[€624]) and increased quality-adjusted life-years (QALYs) (0.0019) compared with NAT and was therefore the dominant
treatment strategy. Tolvaptan was also associated with reduced costs and increased QALYs in the SCLC and pneumonia
subpopulations. The most influential variables in our analysis were reduction in hospital length of stay, duration
of treatment and long term treatment with tolvaptan in SCLC patients.
Conclusions: Tolvaptan represents a cost-effective treatment option in Sweden for hospitalised patients with HN
secondary to SIADH who have either failed to respond to or are unsuitable for fluid restriction.
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Hyponatraemia (HN) is the most common electrolyte
disturbance in clinical practice, occurring in approxi-
mately 15–30 % of hospitalised patients [1, 2]. It is
commonly defined as a serum sodium concentration
([Na+]) <135 mmol/L [2–5], with severe HN defined as
<125 mmol/L [2]. Hyponatraemia is associated with in-
creased mortality, morbidity and length of hospital stay [2].* Correspondence: KO'Reilly@otsuka-europe.com
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(http://creativecommons.org/publicdomain/zeHyponatraemia can be euvolaemic (i.e. without an as-
sociated change in body fluid volume), hypervolaemic
(i.e. body fluid volume is increased), or hypovolaemic
(body fluid volume is decreased). These three types of
HN have different sets of possible aetiologies. The most
common cause of euvolaemic HN is the syndrome of
inappropriate antidiuretic hormone secretion (SIADH)
[3, 6], which is the focus of our analysis. In SIADH
water retention is caused by inappropriate increased re-
lease of, or responsiveness to, antidiuretic hormone
(ADH) [7]. This can be due to malignancy, pneumonia,
central nervous system disorders or certain drugs [7].article is distributed under the terms of the Creative Commons Attribution 4.0
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types of malignancy, it is most commonly observed with
small cell lung cancer (SCLC) and studies have shown a
higher mortality rate in SCLC patients with HN than in
those without [8, 9]. Drug-induced SIADH usually re-
solves upon discontinuation of the medication [7].
Swedish guidelines for HN, published by the Swedish
Endocrine Society and the Swedish Association for Anaes-
thesiology and Intensive Care [1], recommend resolution
of the underlying condition as the primary treatment
strategy in patients with SIADH. If symptoms are mild,
HN secondary to SIADH may be treated with fluid restric-
tion. Diagnosis and treatment should be re-evaluated if
the patient does not respond within 12–24 h. If the symp-
toms are more pronounced the patient will require treat-
ment in intensive care [1]. In patients who do not respond
to or cannot be treated with fluid restriction, symptoms
may exacerbate and patient outcomes may be signficiantly
affected. For patients in whom fluid restriction has
been unsuccessful or is unsuitable, vasopressin receptor
antagonists (i.e., tolvaptan) are recommended [1]. In
clinical practice, subjects with HN, especially if it is associ-
ated with no or mild symptoms, or if initial treatment was
unsuccessful, may often not receive treatment [10].
Tolvaptan, an oral vasopressin V2 receptor antagon-
ist, is the only vaptan approved by the European Medi-
cines Agency (EMA) for the treatment of adult patients
with HN secondary to SIADH in 2009 [11]. Tolvaptan
blocks binding of ADH to the V2 receptor which in-
duces electrolyte-free water excretion. The result is a
reduction in body water without loss of body electro-
lytes, which leads to an increase in serum [Na+] [4, 5].
The cost-effectiveness of tolvaptan for the treatment
of HN secondary to SIADH has never been studied in a
European setting. Worldwide, three studies have previ-
ously evaluated the potential cost impact of tolvaptan in
HN [12–14]; however, one of these was performed in a
different indication (heart failure) (14). Of the remaining
two studies, Dasta et al. [13] considered a US hospital
population with HN secondary to SIADH and observed
a total cost offset, including the acquisition cost of tol-
vaptan, of $694 per admission. The authors estimated
that tolvaptan would be cost-neutral with duration of
therapy of ≥6.78 days. In a South Korean analysis, Lee et al.
[14] found that, in patients hospitalised for treatment and
monitoring of euvolaemic and hypervolaemic HN, tolvap-
tan treatment was less costly and more efficacious com-
pared with placebo.
We have performed an economic evaluation, from a
Swedish societal perspective, to determine the cost-
effectiveness of tolvaptan, compared with no active treat-
ment (NAT) for HN secondary to SIADH in adult patients
who have either failed to respond to fluid restriction or for
whom the use of fluid restriction is not suitable.Methods
Design of the economic evaluation
A cost-utility analysis was conducted. The primary out-
come was the incremental cost-effectiveness ratio (ICER)
expressed as a cost per quality-adjusted life-year (QALY)
in line with Tandvårds- och läkemedelsförmånsverket
(The Dental and Pharmaceutical Benefits Agency [TLV])
guidance at the time of analysis [15]. The base case used
a societal perspective, also in line with TLV guidance.
Tolvaptan was compared with NAT. This choice was
based on advice from clinicians and evidence from the
HN registry, a multi-centre, prospective, observational
study. The HN registry showed that, of patients pro-
vided with fluid restriction as a first therapy, 56 % expe-
rienced a total increase of [Na+] of ≤5 mEq/L and of
these patients, 56 % were not provided a second ther-
apy [10]. This suggests that NAT is a relevant option
widely used in clinical practice, despite being inappro-
priate in many cases.
The economic evaluation considered a hypothetical
cohort of individuals with HN secondary to SIADH who
had either failed to respond to or were unsuitable for
fluid restriction. This population was chosen in line with
current Swedish guidance and clinical practice [1, 16].
For the purpose of the economic evaluation, HN is de-
fined as [Na+] <135 mmol/L and sodium correction is
defined as [Na+] ≥135 mmol/L, consistent with the tol-
vaptan clinical trial programme [4, 5].
Three clinically relevant patient populations were evalu-
ated in the analysis: all patients with HN secondary to
SIADH (‘general SIADH’); the subgroup of patients with
SCLC and HN secondary to SIADH (SCLC cohort); the
subgroup of patients with pneumonia and HN secondary
to SIADH (pneumonia cohort). The SCLC and pneumo-
nia populations were selected as examples of two highly
relevant subpopulations, for which the clinical and patient
pathways are very different. They were chosen to broadly
represent the complex clinical pathway of SIADH.
A 30-day time horizon was chosen in the base case ana-
lysis for the ‘general SIADH’ population, reflecting the
relatively short duration of treatment for HN secondary to
SIADH and the duration of the tolvaptan Phase III clinical
studies [4, 5]. The 30-day time horizon is also thought to
capture all relevant consequences for most patients in this
population. Similarly, a 30-day time horizon was also
deemed appropriate for the pneumonia subgroup, due to
the short duration of treatment for HN secondary to
SIADH in this population. However, based on clinical ex-
pert opinion, a 180-day time horizon was assumed for the
SCLC population.
Future costs and benefits are discounted at a rate of
3.0 % per annum, in line with current TLV guidance, but
due to the short time horizon of the analysis this is
mainly applicable to scenario analyses [15].
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An individual-level model (specifically, a discrete event
simulation [DES]), which simulates multiple clinical out-
comes over time was developed to model the progression
of individuals, one at a time, through multiple inpatient
admissions over the defined time horizon. The DES ap-
proach was adopted in preference to a cohort model
(which is more commonly seen in this type of analysis)
due to the ability to easily incorporate time dependency.
For example, many economic and clinical aspects of HN
secondary to SIADH may occur at rates that change
over time (time to hospital discharge; time to mortality;
time to hospital readmission; time to discontinuation of
tolvaptan).
The flow of hypothetical individuals through the model
and the order in which events may occur are depicted in
Fig. 1. In summary:
1. An individual is admitted to hospital and is
diagnosed with HN secondary to SIADH
2. The individual undergoes active treatment or
receives NAT for HN secondary to SIADH
3. The individual may undergo further treatment for
their underlying condition (such as chemotherapy)
before being discharged
a. In the base case, all individuals are assumed to be
discharged to home
b. Individuals are assumed to have their underlying
condition resolved (‘general SIADH’ and
pneumonia) or not (SCLC) at discharge and this
affects quality of life (QoL) between admissions
4. The individual may die, either during hospitalisation
or following discharge
5. The individual may be readmitted at a later date and
will flow through the model again
6. The individual leaves the model at the end of the set
time horizon, or at death, whichever occurs first,
and a new patient is selected.
The DES was run for 100,000 hypothetical patients to
arrive at a set of outputs representative of a cohort in
each subpopulation, both with and without tolvaptanFig. 1 Event graph depicting flow of patients in modeltreatment. Comparative modelled outputs, other than
QALYs, included hospital length of stay (LOS), readmis-
sions, and mortality.
Data sources
The economic evaluation relies on evidence from several
sources, listed below. A summary of how these sources
inform the required clinical parameters, across the three
base case analyses, is presented in Table 1.
 The Study of Ascending Levels of Tolvaptan in
Hyponatremia I and II (SALT I and SALT II) are both
randomised, placebo-controlled, double-blind trials
examining the effect of tolvaptan on hypervolaemic
and euvolaemic HN of different aetiologies [4, 5].
 The Assessment of epidemiology, patient
characteristics and outcomes Related To patients
with HN/SIADH in Sweden: a population-based
register study (ART) is a retrospective cohort study
conducted using the compulsory population-based
health registers governed by the National Board of
Health and Welfare [17].
 The HN Registry is a global, multicentre (US and
European), prospective, observational study of
current treatment approaches for hospitalised
patients with euvolaemic or hypervolaemic HN [10].
Model inputs
A summary of base case inputs is presented in Table 2.
Health-related QoL (HRQL, in the form of health state
utilities) for the ‘general SIADH’ population were obtained
by mapping SF-12 (12-Item Short Form Health Survey)
responses from SALT I and II to EQ-5D (a standardised
health outcome questionnaire) [18] using a mapping algo-
rithm developed by Gray et al. [19]. Simulated EQ-5D
scores were then used to estimate changes in EQ-5D from
baseline at Day 30 using ordinary least squares regression
as a function of baseline characteristics, treatment arm and
achievement of [Na+] correction at Day 4 (≥135 mmol/L)
(i.e. the definition of sodium correction, in line with a pre-
defined endpoint in SALT I & II [4]). Literature sources
were sought to estimate the baseline utility scores for the
Table 1 Application of clinical data sources in the model base cases
Population modelled
Parameter General SIADH SCLC Pneumonia
Population characteristics HN Registry and ART HN Registry and ART HN Registry and ART
[Na+] correction HN Registry and SALT I & II HN Registry and SALT I & II HN Registry and SALT I & II
Duration of tolvaptan treatment HN Registry Expert clinical opinion Expert clinical opinion
HRQL change SALT I & II SALT I & II SALT I & II
Length of inpatient stay SALT I & II SALT I & II SALT I & II
Inpatient mortality ART ART ART
Readmission ART ART ART
Long-term mortality Swedish life-tables ART Swedish life-tables
Abbreviations: ART the Assessment of epidemiology, patient characteristics and outcomes Related To patients with hyponatraemia/SIADH in Sweden, HN hyponatraemia,
HRQL health related quality of life, SALT the Study of Ascending Levels of Tolvaptan in Hyponatremia, SCLC small cell lung cancer, SIADH syndrome of inappropriate
antidiuretic hormone secretion
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were collected from a number of different sources in-
cluding hospital price lists [22], TLV official price data-
base [23] and Statistics Sweden [24]. The reference year
of the costs was 2013, and costs are given in Swedish
kronor (SEK). Additional details are provided in the
Additional file 1.
Key assumptions
Assumptions had to be made where no suitable data
sources could be identified. Key assumptions concerned
the benefit of correction of HN, which was conservatively
assumed not to affect rates of hospital readmission, in-
patient mortality or long-term mortality. An overview of
other assumptions can be found in the Additional file 1.
Scenario analyses
A number of alternative scenarios were analysed. These
included alternative time horizons of 60, 90 and 180 days
and 1 year for all subpopulations in the model. Alterna-
tive durations of tolvaptan treatment were also analysed,
as well as removing the early discontinuation of treat-
ment rule and different hospital LOS. An SCLC popula-
tion receiving tolvaptan for extended periods, typically
to increase QoL in a palliative care setting, was also con-
sidered as a scenario analysis. The alternative scenarios
tested are described in the Additional file 1.
Sensitivity analysis
Sensitivity analysis is used to explore how changes in model
parameters and assumptions alter the outcomes of the ana-
lysis. All parameters in the model were varied by the 95 %
CI around the mean or, where unavailable, by ±15 %. A tor-
nado diagram, visually representing the results (Fig. 2), was
generated, in which the effect on the net monetary benefit
(NMB) at a willingness-to-pay threshold SEK 1.2 million
was plotted, with variables ordered by the magnitude of
their effect. The NMB applies a monetary value to QALYsand is calculated by rearranging the cost-effectiveness deci-
sion rule to λ ⋅ΔE −ΔC > 0 (λ, willingness to pay threshold;
ΔE, change in effect; ΔC, change in cost) [25]. This ap-
proach was preferred to plotting changes to ICERs directly
to ensure appropriate values were presented in the presence
of negative ICERs.
Results
Base case results for the three different populations, based
on cohorts of 100,000 individually modelled patients, are
presented in Table 3. Detailed results are provided in the
Additional file 1. Tolvaptan was associated with reduced
per patient costs (savings of SEK 2,678 to SEK 8,411[€289
to €908]) and increased incremental QALYs (0.0018 to
0.0028) versus NAT. Tolvaptan was therefore considered
to be the dominant (i.e. both cost-saving and resulting in a
QALY gain) strategy in all three populations.
The results from the scenario analyses are presented in
the Additional file 1. The most important determinants of
cost-effectiveness in our model were reduction in hospital
LOS associated with tolvaptan (removal of this benefit
resulting in ICERs of SEK >1.4 million), duration of treat-
ment with tolvaptan (an increase in treatment duration
resulting in a considerable ICER increase in the ‘all SIADH’,
but not change in the SCLC and pneumonia populations)
and long term treatment with tolvaptan in SCLC patients
(SEK 2.9 million).
The results of univariate sensitivity analyses for the
‘general SIADH’ population are presented in Fig. 2. The
most influential parameters were two of the coefficients
used in the estimation of the duration of tolvaptan treat-
ment; the constant term and baseline [Na+]. When these
were varied between their upper and lower 95 % confi-
dence intervals, they were able to generate NMB < SEK
0 at a willingness-to-pay threshold of SEK 1.2 million. A
recent review of the literature around the value of a stat-
istical life in Sweden suggests a willingness-to-pay
threshold of SEK 1.2 million per QALY [26].
Table 2 Base case inputs by population (data value or type; source)
Model element General SIADH SCLC Pneumonia
Clinical parameters
Mean age (years) 70; ART (with SIADH)a 64; ART (SCLC with SIADH)a 69; ART (pneumonia with
SIADH)a
% Male 33 %; ART (with SIADH)a 31 %; ART (SCLC with SIADH)a 43 %; ART (pneumonia with
SIADH)a











11.50; SALT I & II [4] 11.50; SALT I & II [4] 11.50; SALT I & II [4]
Duration of tolvaptan treatment Mean 3 days; Lognormal survival
distribution; HN Registry (SIADH)b
Mean 4 days; Petereit et al. [28] Mean 3 days; clinical opinion
Early tolvaptan treatment
discontinuation rule
2 days 2 days 2 days
Mean hospital LOS NAT 8.00; SALT I & II (SIADH with
[Na+] <130 mmol/L) [4]
8.00; SALT I & II (SIADH with
[Na+] <130 mmol/L) [4]
8.00; SALT I & II (SIADH with
[Na+] <130 mmol/L) [4]
Percentage reduction hospital
LOS with tolvaptan
20.0 %; SALT I & II (SIADH with
[Na+] <130 mmol/L)c
20.0 %; SALT I & II (SIADH with
[Na+] <130 mmol/L)c
20.0 %; SALT I & II (SIADH with
[Na+] <130 mmol/L)c
Probability inpatient mortality 2.2 %; ART (with SIADH)a 4.4 %; ART (SCLC with SIADH)a 6.2 %; ART (pneumonia with
SIADH)a
Long-term survival Based on age; Swedish
life-tables [24]
Based on disease; Gompertz
distribution from ART (SCLC
with SIADH)
Based on age; Swedish
life-tables [24]
Time to readmission Weibull distribution;
ART (with SIADH)a




Probability of SIADH (and HN)
resolution at end of inpatient
admission
100 %; assumption 88 %; List et al. [39] 100 %; assumption
Time to resolutiond NA in base case NA in base case NA in base case
Costs
Tolvaptan dosing/cost assumption 15/30 mg once dailye 15/30 mg once dailye 15/30 mg once dailye
Care setting for admission Internal medicine clinic Oncology clinic Pulmonary care clinic
Discharge location Home Home Home
Palliative care costs None Applied for a maximum of
84 days (3 months)
None
Chemotherapy costs None Applied once per inpatient stay None
Percentage patients in work
between readmissions
17 %; [40] 0 %; Assumption 17 %; [40]
HRQL
Baseline utility 0.58; SALT I & II [41] 0.61; Loveman et al. [20] with HN
reduction from SALT I & II [41]
0.73; Schuetz et al. [21] with HN
reduction from SALT I & II [41]
Treatment-specific change in
EQ-5D at Day 4
Absolute change in simulated
EQ-5D at Day 30 from
SALT I & II [41]
Absolute change in simulated
EQ-5D at Day 30 from
SALT I & II [41]
Absolute change in simulated
EQ-5D at Day 30 from
SALT I & II [41]
Model structure
Time horizon 30 days 180 days 30 days
Abbreviations: ART The Assessment of epidemiology, patient characteristics and outcomes Related To patients with hyponatraemia/SIADH in Sweden: a
population-based register study, HN hyponatraemia, HRQL health-related quality of life, LOS length of stay, NA not applicable, NAT no alternative treatment,
SALT study of ascending levels of Tolvaptan in Hyponatremia, SCLC small cell lung cancer, SIADH syndrome of inappropriate antidiuretic hormone secretion
aBased on data from ART (unpublished observations)
bAnalysis of HN registry data
cpost-hoc analysis of SALT1 and SALT-2
dIf resolution did not occur as an inpatient
e15/30 mg daily associated with equal cost
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Fig. 2 Tornado diagram showing effect of varying parameters on NMB (threshold = SEK 1.2 m). Abbreviations: HRQL, health-related quality of life;
LOS, length of stay; NAT, no active treatment; NMB, net monetary benefit; OR, odds ratio; SEK, Swedish kronor
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The present analysis assessed the cost-effectiveness of tol-
vaptan in three populations of patients with HN secondary
to SIADH for whom the alternative treatment option is
NAT. In the base case for the ‘general SIADH’ population,
tolvaptan was the dominant strategy compared with NAT,
as it was associated with a reduction in cost and an incre-
mental QALY gain. Cost savings are predicted based on
reductions in LOS, whilst QALY gains are a consequence
of associated improvements in HRQL. Compared with
NAT, tolvaptan was also the dominant strategy in the
SCLC and pneumonia populations, associated with incre-
mental cost savings and an incremental QALY gain. TheTable 3 Base case results (per patient)
NAT Tolvaptan Incremental
General SIADH
Total costs SEK 45,462 SEK 39,683 -SEK 5,779
QALYs 0.05381 0.05567 0.00186
ICER Tolvaptan dominates
SCLC
Total costs SEK 372,717 SEK 364,306 -SEK 8,411
QALYs 0.21817 0.22101 0.00284
ICER Tolvaptan dominates
Pneumonia
Total costs SEK 26,541 SEK 23,863 -SEK 2,678
QALYs 0.05689 0.05868 0.00179
ICER Tolvaptan dominates
Abbreviations: HRQL health-related quality-of-life, ICER incremental cost-effectiveness
ratio, NAT no active treatment, QALY quality-adjusted life-year, SCLC small-cell lung
cancer, SIADH syndrome of inappropriate antidiuretic hormone secretionresults were sensitive to assumptions relating to the
duration of tolvaptan treatment, LOS associated with
NAT and the reduction in LOS associated with tolvap-
tan treatment.
The data used to calculate LOS and HRQL was obtained
from the SALT I and SALT II clinical trials [4, 5]. The pa-
tients in the trials were treatment-naïve, whereas patients
in the model had either failed to respond to fluid restric-
tion or the use of fluid restriction was not suitable. Patients
that fail to respond to fluid restriction may have more
severe forms of SIADH and may be unable to excrete
electrolyte-free water [27]. Therefore, they may respond
differently to tolvaptan compared with the patients in
SALT I and SALT II. Although the assumed positioning of
tolvaptan in the model may be considered a limitation of
the analysis, the positioning was based on Swedish guide-
lines for HN [1]. Furthermore, there are indications, from
small case series [28, 29] that tolvaptan quickly restores
serum [Na+] concentrations in a population consistent
with that modelled (i.e. in patients with HN secondary to
SIADH who have failed fluid restriction or for whom fluid
restriction is unsuitable).
The model assumes a reduction in LOS of 20 % based
on the overall reduction observed in patients receiving tol-
vaptan compared with patients receiving placebo in the
SIADH population of the SALT trials [4]. This reduction
was not statistically significant, and the studies were not
powered to demonstrate a difference in reduction of LOS.
However, a subgroup analysis of euvolaemic patients with
HN in the investigator-diagnosed SIADH group, combined
with patients classified as ‘other’ (all patients not meeting
clinical criteria for diagnosis of heart failure or cirrhosis),
demonstrated a significantly shortened LOS favouring
Jamookeeah et al. BMC Endocrine Disorders  (2016) 16:22 Page 7 of 9tolvaptan (4.70 ± 3.89 versus 8.40 ± 9.67 days; p = 0.045; a
reduction of 44 %) [4]. These preliminary findings should
ideally be confirmed by clinical trials designed to evaluate
this outcome. A reduction of LOS, as demonstrated in the
SALT trials, is supported by preliminary data from the HN
registry [30] showing that the median LOS from the start
of treatment was shortest for tolvaptan (3 days) and longest
for no treatment (6 days). Published data in HN relevant to
the current analysis are limited, not least due to the
complexity of the condition and the clinical pathway.
Every effort was made to identify the most relevant data
for the model, using real word data sources where pos-
sible. Sweden-specific data were used where available.
Basing model LOS data in the SCLC and pneumonia
populations on evidence from the SALT trials may be
considered a source of uncertainty, as the percentage of
patients in the study population with SCLC or pneumo-
nia is not known. The patients enrolled in these studies
had either euvolaemic or hypervolaemic HN associated
with chronic heart failure, cirrhosis or SIADH (with no
condition affecting >50 % of patients) [5]. Our approach
is also supported by other studies, which suggest that the
mean LOS assumed for the NATarm of the model (8 days)
is reasonable for the pneumonia population [31–33]. Data
for the SCLC population are scarce; Salahudeen et al. [34]
report mean (SD) LOS of 10.3 (10.0) for patients with HN
in a mixed US oncology population.
Patient baseline characteristics were derived from the
ART study, which identifies HN patients using ICD-9/10
codes. This method of identifying patients has high spe-
cificity, but low sensitivity [35]. However, the data are
specific to Sweden and include patients from all three
populations modelled. The ART study is therefore the
most relevant source of patient characteristics data for
this analysis.
It remains unclear to what extent [Na+] correction or
improvement is associated with improved long-term out-
comes. There is some evidence that HN in hospitalised
patients is associated with increased mortality (5-year data
are available), with mild HN showing similar mortality
rates to severe HN [36]. The model assumes no mortality
benefit associated with [Na+] correction and does not ex-
plicitly include the benefits of treatments which may be
administered to achieve [Na+] correction. The model as-
sumes no residual HRQL or cost benefits associated with
tolvaptan following discontinuation, and other longer-
term benefits, such as any benefits of [Na+] correction on
readmissions, are ignored by the model, and therefore
cost-effectivness may be underestimated.
Another possible factor not considered in our analysis,
due to the lack of data, is the possibility of overcorrection,
which may occur due to unexpected diuresis after
resolution of the cause of the original water retention.
Overcorrection of HN can have severe neurologicalconsequences due to demyelination occurring in the
brain [37].
In modelling this condition, there was dissociation
between the treatment effect (e.g. changes in [Na+] and
HRQL. HRQL is based on reported QoL at Day 30 of
SALT I and II. Transient adverse events could therefore
have been missed, which would lead to an underestima-
tion of HRQL losses. Although the assumption that 100 %
of the ‘general SIADH’ population resolve their underlying
condition following discharge is an over-simplification, the
effect on incremental cost-effectiveness is likely to be min-
imal (please see Section 1.1.6 of the Additional file 1 for
the underlying reasoning). Modelling HN secondary to
SIADH without building several disease-specific models
required a high degree of generalisation.
Published data relevant to the current analysis are lim-
ited but the best available data have been utilised from
the randomised SALT trials. The main costs and benefits
associated with short-term tolvaptan use are included in
the model, but data limitations could lead to additional
benefits not being accounted for, resulting in a possible
under-estimation of cost-effectiveness. Despite a possible
underestimation of cost-effectiveness, due to data limita-
tions, the current analysis shows that tolvaptan treat-
ment is associated with cost savings. The results of our
analysis will be helpful to clinicians in the field of HN in
establishing appropriate treatment strategies for patients
with euvolaemic HN in the hospital setting.Conclusion
This is the first cost-utility analysis of tolvaptan for the
treatment of HN secondary to SIADH in a European
setting. Treatment with tolvaptan was associated with
reduced costs and better health outcomes (measured as
QALYs) compared with NAT in the ‘general SIADH’,
SCLC and pneumonia populations considered in this
economic evaluation. Based on the assumptions within
this evaluation, tolvaptan therefore represents a cost-
effective treatment option for patients with HN second-
ary to SIADH who have either failed to response to
fluid restriction or for whom the use of fluid restriction
is not suitable.Ethics approval and consent to participate
Not applicable. We conducted an economical assessment
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